Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
NCT04330625
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class
Stopped
Lack of enrollment
Conditions
Hyperglycemia Drug Induced
Interventions
BIOLOGICAL:
REMD-477
Sponsor
Duke University